RCS - Spexis AG - Spexis to present at BioEquity Europe 2022
12/05/2022 08:45
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220512:nRSL2418La&default-theme=true
RNS Number : 2418L Spexis AG 12 May 2022
Spexis to present at BioEquity Europe 2022
Spexis AG / Key word(s): Conference
Spexis to present at BioEquity Europe 2022
12.05.2022 / 07:30 CET
Allschwil, Switzerland, May 12, 2022
Spexis to present at BioEquity Europe 2022
Spexis AG (SIX: SPEX) today announced that that the company will present at
BioEquity Europe, taking place May 17 & 18, 2022. Jeff Wager, CEO of
Spexis, will provide an overview of the company and its pipeline and will be
available to participate in one-on-one meetings with investors who are
registered to attend the conference.
The presentation is now available to conference registrants. For more
information on the conference, visit the BioEquity website
(https://conferences.biocentury.com/bioequity-europe) .
For further information please contact:
For Investors: For Media:
Hernan Levett
Dr. Stephan Feldhaus
Chief Financial Officer
Feldhaus & Partner
Spexis AG.
+41 79 865 92 56
+41 61 567 16 00 feldhaus@feldhaus-partner.ch (mailto:feldhaus@feldhaus-partner.ch)
IR@spexisbio.com (mailto:IR@spexisbio.com)
Raimund Gabriel
Dr. Brigitte Keller/Laurie Doyle
MC Services
MC Services
spexis@mc-services.eu (mailto:spexis@mc-services.eu) spexis@mc-services.eu (mailto:spexis@mc-services.eu)
Ph: +49 89 210 228 0
Europe: +49 89 210 228 0
U.S.: +1 339 832 0752
About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland, focused on rare diseases and oncology. The current pipeline of
the company is a combination of two legacy companies, Polyphor AG and
EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
under the symbol SIX:SPEX. For further information please
visit: www.spexisbio.com (https://spexisbio.com/) .
Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only as of the date of this communication. Spexis disclaims any
intention or obligation to update and revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
End of Media Release
About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland, focused on rare diseases and oncology. The current pipeline of
the company is a combination of two legacy companies, Polyphor AG and
EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined
company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange
under the symbol SIX:SPEX. For further information please
visit: www.spexisbio.com (https://spexisbio.com/) .
Disclaimer
This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only as of the date of this communication. Spexis disclaims any
intention or obligation to update and revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
End of Media Release
Language: English
Company: Spexis AG
Hegenheimermattweg 125
4123 Allschwil
Switzerland
Phone: +41 61 567 1600
Fax: +41 61 567 1601
E-mail: info@spexisbio.com
Internet: www.spexisbio.com
ISIN: CH0106213793
Valor: SPEX
Listed: SIX Swiss Exchange
EQS News ID: 1350291
End of News EQS News Service
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAUUVVRUVUVARR